MedTrace Logo

Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients

NCT02518529 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2015-08-10

No results posted yet for this study

Summary

Open-label, multicenter study to assess 250µg/0.2ml G17DT injection at weeks 0, 2 and 6. At or after week 20 and up to and including week 44. Subjects who raised antibodies to G17DT were given an additional dose of 125µg/0.1ml or 250µg/0.2ml G17DT between weeks 20-44 (study duration 52 weeks).

Conditions

Interventions

BIOLOGICAL

G17DT

Sponsors & Collaborators

  • PPD Development, LP

    collaborator INDUSTRY

  • ChapelPharma Ltd

    collaborator UNKNOWN

  • Cancer Advances Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-28
Primary Completion
2002-12-31
Completion
2002-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02518529 on ClinicalTrials.gov